On ECHEMI
Home > Drugs > Disseminated intravascular coagulation
Disseminated intravascular coagulation
Under the action of certain pathogenic factors, coagulation factors and platelets are activated, a large amount of procoagulants enter the blood, thrombin increases, and extensive microthrombi are formed in the microcirculation. A large amount of coagulation factors and platelets are consumed in the formation of microthrombi, and the secondary fibrinolysis function is enhanced, leading to clinical manifestations such as bleeding, shock, organ dysfunction and hemolytic anemia in patients. This pathological process is called DIC.
  • Site of disease:

    Blood vessels whole body
  • Infectious :

    Not contagious
  • Frequent population:

    Infectious diseases and malignant diseases are common
  • Related symptoms:

    Disorders of coagulation factor function stomach ache difficulty breathing convulsions skin bleeding spots
  • Concurrent disease:

Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is better than other antifibrinolytic drugs in stopping bleeding, but
Manufacturer:

Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:

Hubei Jinyao Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.

Tranexamic acid capsules
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for ① trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (tPA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or alleviate tooth extraction or
Human fibrinogen
Indication: 1. Congenital hypofibrinogenemia or deficiency. 2. Acquired hypofibrinogenemia: severe liver damage; liver cirrhosis; disseminated intravascular coagulation; postpartum hemorrhage and coagulation disorders caused by fibrinogen deficiency due to major surgery, trauma or internal bleeding.
Manufacturer:

Shenzhen Weiguang Biological Products Co., Ltd.

Human fibrinogen
Indication: 1. Congenital hypofibrinogenemia or deficiency. 2. Acquired hypofibrinogenemia: severe liver damage; liver cirrhosis; disseminated intravascular coagulation; postpartum hemorrhage and coagulation disorders caused by fibrinogen deficiency due to major surgery, trauma or internal bleeding.
Manufacturer:

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.